FGF2在烧伤创面愈合中的作用:从分子功能到临床应用的系统综述
FGF2通过促进成纤维细胞增殖、角质形成细胞迁移、血管生成与基质重组加速创面修复;局部制剂可缩短部分厚度烧伤愈合时间并改善瘢痕质量,新型载体提升生物利用度与局部持续效应;疗效与剂量及创面特征相关,安全性良好。
要点
- FGF2经促增殖、促血管生成与基质重组加速烧伤创面修复。
- 局部FGF2制剂可缩短部分厚度烧伤愈合时间并改善瘢痕质量。
- 水凝胶、脂质体与基因激活基质等载体可提升生物利用度与局部持续效应。
核心结论
- FGF2在烧伤治疗中展现再生与免疫调节潜力。
- 更广泛推广需统一监管评价、优化递送系统并开展多中心验证,以明确其在精准烧伤治疗中的定位。
研究设计与样本
- 系统综述,遵循PRISMA 2020标准,检索PubMed、EMBASE、Web of Science、Cochrane与Google Scholar。
- 采用Newcastle-Ottawa量表、SYRCLE工具与牛津证据等级评估方法学质量与偏倚风险。
主要发现
- FGF2通过刺激成纤维细胞增殖、角质形成细胞迁移、血管生成与基质组织化加速修复。
- 局部FGF2制剂缩短部分厚度烧伤愈合时间并改善瘢痕质量。
- 水凝胶、脂质体与基因激活基质等新型载体增强生物利用度与局部持续效应。
- 在糖尿病与复杂烧伤模型中,FGF2减轻炎症、维持屏障完整性并促进再上皮化。
- 疗效取决于剂量与创面特征;研究报告安全性良好,不良事件轻微。
临床怎么用
- 部分厚度烧伤可考虑局部FGF2制剂以缩短愈合时间并改善瘢痕质量。
- 选择载体时关注水凝胶、脂质体与基因激活基质等提升生物利用度的递送策略。
- 应用时需结合剂量与创面特征个体化评估疗效。
局限性
- 需统一监管评价、优化递送系统并开展多中心验证以明确其临床定位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burn injuries trigger complex inflammatory and metabolic cascades that impair wound healing and increase morbidity. Fibroblast growth factor 2 (FGF2), a potent mediator of cellular proliferation, angiogenesis, and extracellular matrix remodeling, has emerged as a promising therapeutic agent in burn care. This systematic review evaluated the biological mechanisms, delivery strategies, and clinical outcomes associated with FGF2 in burn wound healing to clarify its therapeutic value and translational potential. Following PRISMA 2020 standards, a structured literature search was conducted across PubMed, EMBASE, Web of Science, Cochrane, and Google Scholar to identify studies investigating FGF2 in thermal injuries. Eligible records included clinical trials, in vivo models, and in vitro experiments. Methodological quality and risk of bias were assessed using the Newcastle-Ottawa Scale, the SYRCLE tool, and the Oxford Levels of Evidence. Thirty-three studies (1992-2025) met inclusion criteria, encompassing randomized controlled trials, animal models, and mechanistic analyses. Fibroblast growth factor 2 accelerated repair by stimulating fibroblast proliferation, keratinocyte migration, angiogenesis, and matrix organization. Topical FGF2 formulations shortened healing time and improved scar quality in partial-thickness burns. Innovative carriers, including hydrogels, liposomes, and gene-activated matrices, enhanced bioavailability and sustained local effects. In diabetic and complex burn models, FGF2 mitigated inflammation, preserved barrier integrity, and promoted re-epithelialization. Efficacy depended on dosage and wound characteristics. Studies reported favorable safety profiles with minimal and mild adverse events. Fibroblast growth factor 2 demonstrates regenerative and immunomodulatory potential in burn management. Broader adoption requires harmonized regulatory evaluation, optimized delivery systems, and multicenter validation to define its role in precision-guided burn care.
引用
- Niederegger T, Schaschinger T, Brandt J, et al. FGF2 in Burn Wound Healing: From Molecular Function to Clinical Application-A Systematic Review. J Burn Care Res. 2026. PMID: 41665267. doi:10.1093/jbcr/irag020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。